Format

Send to

Choose Destination
Postgrad Med. 2019 Mar;131(2):103-108. doi: 10.1080/00325481.2019.1568792. Epub 2019 Jan 21.

High burden and low awareness of toxoplasmosis in the United States.

Author information

1
a Department of Medical Affairs , Vyera Pharmaceuticals , New York , NY , USA.
2
b Unit of PharmacoEpidemiology & PharmacoEconomics, Department of Pharmacy , University of Groningen , Groningen , The Netherlands.
3
c Global Market Access Solutions , Mooresville , NC , USA.

Abstract

Toxoplasmosis, a disease with diverse clinical manifestations, caused by infection with the Apicomplexan parasite, Toxoplasma gondii (T. gondii), is a major source of morbidity and mortality in the United States. Although toxoplasmosis prevalence and mortality have declined over the past two decades, the CDC considers this disease a neglected parasitic infection requiring public health action. Here, we overview the literature to bring attention to the prevalence of the disease in the United States, and high economic burden associated with the disease. The conclusions to be drawn are clear: there is low awareness and underestimation of the disease burden amongst healthcare professionals; a high economic burden associated with the disease; relapse rates to treatment represent additional mortality and morbidity and further costs for the healthcare system; and better treatments are necessary to combat this public health threat.

KEYWORDS:

Toxoplasmosis; United States; awareness; disease burden; economic burden; prevalence; recurrence; treatment

PMID:
30638425
DOI:
10.1080/00325481.2019.1568792
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center